Consensus on How to Conduct Follow-Up in Peripheral Vascular Disease

Peripheral vascular disease involves multiple areas and, therefore, can have very different presentations (from complete lack of symptoms to disabling symptoms). Depending on clinical presentation, general condition, anatomical localization, and lesion extension, revascularization can be indicated alongside optimal medical treatment.

Seguridad de los balones con paclitaxel en enfermedad vascular periférica

In 2017, guidelines with indications for revascularization were published; however, maintaining long-term patency can be challenging regardless of the strategy.

The rationale for follow-up is to optimize strategies to reduce the number of cardiovascular events, reduce disease progression, avoid symptom recurrence, and avoid new interventions.

Doppler echocardiography is the cornerstone in the identification of revascularization failure. Other non-invasive methods, such as the ankle brachial index, computerized tomography, or magnetic resonance, can optimize follow-up in specific situations.


Read also: Secondary Prevention: A Responsibility We Should Not Delegate.


In the case of carotid disease, for example, the (still controversial) recommendation is follow-up with Doppler ultrasound at 1 month, 6 months, and 1 year after endarterectomy or angioplasty. Beyond the initial 2 years after revascularization, in the absence of contralateral disease, we can consider follow-up every 2 or 3 years. However, (at least) annual clinical follow-up is mandatory.

In the case of lower limbs treated with vein grafts (also with a lack of solid evidence), we should conduct a Doppler echocardiography between weeks 4 and 6, and also at 3, 6, 12, and 24 months after the surgery. Clinical surveillance is lifelong, particularly for patients with critical ischemia.

If lower limb revascularization was endovascular, the recommendation is a Doppler echocardiography within the first month and, if results are normal, assessment at 6 and 12 months. If the initial Doppler echocardiography is abnormal, such result warrants closer follow-up and case-by-case assessment. Doppler usefulness one year after the intervention in asymptomatic patients has not been proven and, therefore, cannot be recommended as routine surveillance.


Read also: Benefit of Anticoagulation in the Elderly with Atrial Fibrillation.


All these patients must be assessed globally, considering all their risk factors, systematic exercise, and aggressive medical treatment.

This document also contributes information on how to follow up the rest of the spectrum of patients with peripheral vascular disease.

PIIS1078588419305143

Original title:: Follow-up of Patients After Revascularization for Peripheral Arterial Diseases: A Consensus Document From the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery.

Reference: Maarit Venermo et al. Eur J Vasc Endovasc Surg (2019) 58, 641e653.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...